| Name | Title | Contact Details |
|---|
Arisaph Pharmaceuticals is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
BioDuro-Sundia provide its biopharma customers a single end-to-end solution from early stage drug discovery to late stage manufacturing.
Luzsana Biotechnology™ is a new kind of biotech company with a mission to make innovative medicines available, accessible, and affordable to anyone, anywhere.
Novartis Consumer Health Inc is a Big Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.